Publications by authors named "Dominik P Modest"

Claim this Profile
I
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in Wild-Type Metastatic Colorectal Cancer.
Arndt Stahler, Dominik Paul Modest, Sebastian Stintzing, Beatrice Borelli, Theresa Keller

J Clin Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials.
Alexej Ballhausen, Federica Morano, Arndt Stahler, Sara Lonardi, Andreas Jay Kind, Dominik Paul Modest

Br J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis.
Alessandra Raimondi, Gabriele Tinè, Alexej Ballhausen, Sara Lonardi, David Tougeron, Dominik Paul Modest

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).
Lena Weiss, Sebastian Stintzing, Dominik Paul Modest, Arndt Stahler, Ludwig Fischer von Weikersthal

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial.
Kathrin Heinrich, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Dominik Paul Modest

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Radiochemotherapy and Total Neoadjuvant Therapy in the Management of Locally Advanced Rectal Cancer.
Mücahit Yigit, Siyer Roohani, Annika Kurreck, Robert Siegel, Dominik P Modest

Cureus· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 - FFCD-GONO - ENGIC 02 - FOLFIRINOX SBA phase II randomized trial.
Thomas Aparicio, Anthony Turpin, Aziz Zaanan, Christelle de la Fouchardière, Karine Le Malicot, Dominik Paul Modest

Dig Liver Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial.
Alexej Ballhausen, Susanna Swoboda, David Horst, Stefan Fruehauf, Ullrich Graeven, Dominik P Modest

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: Rationale and design of the EMPATICC trial.
Markus S Anker, Amir A Mahabadi, Matthias Totzeck, Mitra Tewes, Raluca Mincu, Dominik P Modest

Eur J Heart Fail· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials.
Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, Yoshiaki Nakamura, Simone Oldani, Dominik Paul Modest

J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Prognostic Role of Frailty and Its Recognition With Simple FRAIL and Fried Frailty Questionnaires in Advanced Cancer Patients.
Pia Weinländer, Sara Hadzibegovic, Jan Porthun, Lucie Kretzler, Ruben Evertz, Dominik Paul Modest

J Cachexia Sarcopenia Muscle· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial.
Julien Taieb, Dominik P Modest, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with KRAS-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial.
Dominik Paul Modest, Marwan Fakih, Lisa Salvatore, Taito Esaki, David Páez Lopez-Bravo

Lancet Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and echocardiographic phenotype of cardiac wasting in patients with advanced cancer.
Markus S Anker, Muhammad Shahzeb Khan, Anja Nikolski, Jan Porthun, Muhammad Sameer Arshad, Dominik P Modest

Eur J Heart Fail· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial).
Markus S Anker, Amir A Mahabadi, Matthias Totzeck, Mitra Tewes, Muhammad Shahzeb Khan, Dominik P Modest

Eur Heart J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory G12C Colorectal Cancer.
Filippo Pietrantonio, Lisa Salvatore, Taito Esaki, Dominik Paul Modest, David Paez Lopez-Bravo

J Clin Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival in the CAIRO5 Clinical Trial.
Alexej Ballhausen, Dominik Paul Modest

JAMA Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306.
Julian Walter Holch, Alexander J Ohnmacht, Sebastian Stintzing, Kathrin Heinrich, Lena Weiss, Dominik Paul Modest

Eur J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer.
Lena Weiss, Sebastian Stintzing, Arndt Stahler, C Benedikt Westphalen, Ludwig Fischer von Weikersthal, Dominik Paul Modest

Eur J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study.
Sebastian Stintzing, Susanne Klein-Scory, Ludwig Fischer von Weikersthal, Martin Fuchs, Florian Kaiser, Dominik Paul Modest

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 study.
Susanne Klein-Scory, Alexander Baraniskin, Wolff Schmiegel, Thomas Mika, Roland Schroers, Dominik P Modest

Mol Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solidifying local ablation in the treatment of small-size colorectal liver metastasis.
Laura Stöffler, Dominik Paul Modest, Johann Pratschke, Philipp Konstantin Haber

Lancet Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender-based variations in surgical management of colorectal liver metastases: comprehensive analysis.
Pia F Koch, Kristina Ludwig, Karl H Hillebrandt, Hannes Freitag, Moritz Blank, Dominik Paul Modest

BMC Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial.
Arndt Stahler, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Lothar Müller, Dominik P Modest

EClinicalMedicine· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flow Cytometric Assessment of FcγRIIIa-V158F Polymorphisms and NK Cell Mediated ADCC Revealed Reduced NK Cell Functionality in Colorectal Cancer Patients.
Phillip Schiele, Stefan Kolling, Stanislav Rosnev, Charlotte Junkuhn, Anna Luzie Walter, Dominik Paul Modest

Cells· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis